Table 3.
Development of P8 score for HBV-ACLF prognosis.
| Multivariate Cox proportional-hazards regression | ||||
|---|---|---|---|---|
| Covariate | b | P-value | RH | 95% CI of RH |
| GC | 0.4903 | 0.0047 | 1.6328 | 1.1646 to 2.2893 |
| HRG | -0.6390 | <0.0001 | 0.5278 | 0.4003 to 0.6960 |
| HPR | 0.3335 | 0.0005 | 1.3958 | 1.1579 to 1.6827 |
| SERPINA6 | -0.2866 | 0.0002 | 0.7508 | 0.6454 to 0.8733 |
| INR | 1.4392 | <0.0001 | 4.2174 | 2.5552 to 6.9608 |
| Age | 0.05412 | 0.0002 | 1.0556 | 1.0265 to 1.0856 |
| NEU | 0.2145 | <0.0001 | 1.2392 | 1.1180 to 1.3736 |
| Total protein | -0.09234 | 0.0004 | 0.9118 | 0.8667 to 0.9593 |
| Protein markers description | ||||
| Gene | Protein | Function | ||
| GC | Vitamin D-binding protein | vitamin D transport, enhancement of the chemotactic activity for neutrophil in inflammation, macrophage activation | ||
| HRG | Histidine-rich glycoprotein | immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis | ||
| HPR | Haptoglobin-related protein | HDL particle associated, immune response, iron/heme metabolism | ||
| SERPINA6 | Corticosteroid binding globulin (Transcortin) | glucocorticoids transport | ||
Model summary: Chi-squared=60.851, P < 0.0001.